Sudan Loganathan
Stock Analyst at Stephens & Co.
(0.57)
# 3,810
Out of 4,783 analysts
35
Total ratings
22.22%
Success rate
-24.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELEV Elevation Oncology | Downgrades: Equal-Weight | $5 | $0.27 | +1,769.16% | 4 | Mar 24, 2025 | |
| IMNM Immunome | Reiterates: Overweight | $30 | $7.25 | +314.08% | 2 | Mar 20, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Overweight | $33 | $24.95 | +32.26% | 2 | Feb 27, 2025 | |
| ADCT ADC Therapeutics | Maintains: Overweight | $6 → $8 | $1.48 | +442.37% | 2 | Feb 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $50 | $17.26 | +189.69% | 2 | Feb 14, 2025 | |
| EXEL Exelixis | Reiterates: Equal-Weight | $29 | $37.39 | -22.44% | 4 | Feb 12, 2025 | |
| BCYC Bicycle Therapeutics | Reiterates: Equal-Weight | $15 | $9.09 | +65.11% | 2 | Jan 22, 2025 | |
| NRIX Nurix Therapeutics | Reiterates: Overweight | $31 | $12.66 | +144.96% | 3 | Jan 21, 2025 | |
| KYMR Kymera Therapeutics | Reiterates: Overweight | $60 | $30.29 | +98.09% | 2 | Jan 21, 2025 | |
| BPMC Blueprint Medicines | Reiterates: Overweight | $140 | $90.81 | +54.17% | 2 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.74 | +188.18% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $4 | $1.86 | +115.63% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $55 | $7.98 | +589.22% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13 | $1.06 | +1,132.23% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $13.15 | +90.11% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $0.44 | +1,038.43% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.75 | +1,046.13% | 1 | May 14, 2024 |
Elevation Oncology
Mar 24, 2025
Downgrades: Equal-Weight
Price Target: $5
Current: $0.27
Upside: +1,769.16%
Immunome
Mar 20, 2025
Reiterates: Overweight
Price Target: $30
Current: $7.25
Upside: +314.08%
Catalyst Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $24.95
Upside: +32.26%
ADC Therapeutics
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $1.48
Upside: +442.37%
IDEAYA Biosciences
Feb 14, 2025
Reiterates: Overweight
Price Target: $50
Current: $17.26
Upside: +189.69%
Exelixis
Feb 12, 2025
Reiterates: Equal-Weight
Price Target: $29
Current: $37.39
Upside: -22.44%
Bicycle Therapeutics
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $9.09
Upside: +65.11%
Nurix Therapeutics
Jan 21, 2025
Reiterates: Overweight
Price Target: $31
Current: $12.66
Upside: +144.96%
Kymera Therapeutics
Jan 21, 2025
Reiterates: Overweight
Price Target: $60
Current: $30.29
Upside: +98.09%
Blueprint Medicines
Jan 2, 2025
Reiterates: Overweight
Price Target: $140
Current: $90.81
Upside: +54.17%
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.74
Upside: +188.18%
Nov 18, 2024
Initiates: Equal-Weight
Price Target: $4
Current: $1.86
Upside: +115.63%
Nov 18, 2024
Initiates: Overweight
Price Target: $55
Current: $7.98
Upside: +589.22%
Nov 8, 2024
Initiates: Overweight
Price Target: $13
Current: $1.06
Upside: +1,132.23%
Aug 6, 2024
Reiterates: Overweight
Price Target: $25
Current: $13.15
Upside: +90.11%
May 24, 2024
Reiterates: Overweight
Price Target: $5
Current: $0.44
Upside: +1,038.43%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $1.75
Upside: +1,046.13%